BioLife Solutions (BLFS)

• Market cap: $1.22B
• 1 day: -0.66%
• 5 days: 4.77%
• 1 month: 14.62%
• 3 months: 14.47%
• 6 months: 1.27%
• Year to date: -2.67%
• 1 year: -1.92%
• 5 years: 23.21%
• 10 years: 1,174.00%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Employees: 159

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

61% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 49

38% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 24

2.31% more ownership

Funds ownership: 102.48% [Q1] → 104.79% (+2.31%) [Q2]

2% more funds holding

Funds holding: 188 [Q1] → 191 (+3) [Q2]

5% less capital invested

Capital invested by funds: $1.13B [Q1] → $1.07B (-$52.8M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $32 26% upside
• Avg. target: $32 26% upside
• High target: $32 26% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen

26% upside $32

Buy Maintained

8 Aug 2025